Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

Role of an Indole-Thiazolidine Molecule PPAR Pan-Agonist and COX Inhibitor on Inflammation and Microcirculatory Damage in Acute Gastric Lesions

  • José Roberto Santin,

    Affiliation Laboratory of Experimental Toxicology, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil

    ⨯
  • Isabel Daufenback Machado,

    Affiliation Laboratory of Experimental Toxicology, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil

    ⨯
  • Stephen F. P. Rodrigues,

    Affiliation Laboratory of Experimental Toxicology, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil

    ⨯
  • Simone Teixeira,

    Affiliation Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil

    ⨯
  • Marcelo N. Muscará,

    Affiliation Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil

    ⨯
  • Suely Lins Galdino,

    Affiliation Department of Chemistry, Federal University of Pernambuco, Pernabumbuco, Recife, Brazil

    ⨯
  • Ivan da Rocha Pitta,

    Affiliation Department of Chemistry, Federal University of Pernambuco, Pernabumbuco, Recife, Brazil

    ⨯
  • Sandra H. P. Farsky

    sfarsky@usp.br

    Affiliation Laboratory of Experimental Toxicology, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil

    ⨯

Abstract

The present study aimed to show the in vivo mechanisms of action of an indole-thiazolidine molecule peroxisome-proliferator activated receptor pan-agonist (PPAR pan) and cyclooxygenase (COX) inhibitor, LYSO-7, in an ethanol/HCl-induced (Et/HCl) gastric lesion model. Swiss male mice were treated with vehicle, LYSO-7 or Bezafibrate (p.o.) 1 hour before oral administration of Et/HCl (60%/0.03M). In another set of assays, animals were injected i.p. with an anti-granulocyte antibody, GW9962 or L-NG-nitroarginine methyl ester (L-NAME) before treatment. One hour after Et/HCl administration, neutrophils were quantified in the blood and bone marrow and the gastric microcirculatory network was studied in situ. The gastric tissue was used to quantify the percentage of damaged area, as well as myeloperoxidase (MPO), inducible nitric oxide synthase (iNOS), endothelial nitric oxide synthase (eNOS) protein and PPARγ protein and gene expression. Acid secretion was evaluated by the pylorus ligation model. LYSO-7 or Bezafibrate treatment reduced the necrotic area. LYSO-7 treatment enhanced PPARγ gene and protein expression in the stomach, and impaired local neutrophil influx and stasis of the microcirculatory network caused by Et/HCl administration. The effect seemed to be due to PPARγ agonist activity, as the LYSO-7 effect was abolished in GW9962 pre-treated mice. The reversal of microcirculatory stasis, but not neutrophil influx, was mediated by nitric oxide (NO), as L-NAME pre-treatment abolished the LYSO-7-mediated reestablishment of microcirculatory blood flow. This effect may depend on enhanced eNOS protein expression in injured gastric tissue. The pH and concentration of H+ in the stomach were not modified by LYSO-7 treatment. In addition, LYSO-7 may induce less toxicity, as 28 days of oral treatment did not induce weight loss, as detected in pioglitazone treated mice. Thus, we show that LYSO-7 may be an effective treatment for gastric lesions by controlling neutrophil influx and microcirculatory blood flow mediated by NO.

Citation: Santin JR, Daufenback Machado I, Rodrigues SFP, Teixeira S, Muscará MN, Lins Galdino S, et al. (2013) Role of an Indole-Thiazolidine Molecule PPAR Pan-Agonist and COX Inhibitor on Inflammation and Microcirculatory Damage in Acute Gastric Lesions. PLoS ONE 8(10): e76894. https://doi.org/10.1371/journal.pone.0076894

Editor: Valli De Re, Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Italy

Received: May 14, 2013; Accepted: August 27, 2013; Published: October 4, 2013

Copyright: © 2013 Santin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors thank FAPESP for financial support (Grants No. 2010/17175-0 and 2011/01848-8). MN Muscará, SL Galdino, IR Pitta and SHP Farsky are fellow of the Conselho Nacional de Pesquisa e Tecnologia (CNPq). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Gastric ulcers, a chronic disease that affects millions of people worldwide, are considered a global health problem and are linked to gastric cancer [1,2]. The genesis of the disease is associated with an imbalance of endogenous protective agents and aggressors to the gastric mucosa. Moreover, exogenous factors, such as stress and the excessive intake of non-steroidal anti-inflammatory drugs (NSAIDs) or alcohol may also cause gastric injury. Experimental models using ethanol/HCl (Et/HCl) to induce gastric ulcers have been recently employed to study the genesis and progression of gastric lesions and to evaluate therapeutic approaches [3–7]. Alcohol intake causes mucosal edema, hemorrhage, sub-epithelial cell exfoliation, and infiltration of inflammatory cells. These latter cells release chemical mediators, which contribute to vasoconstriction/ischemia and stasis in the microcirculation, leading to the death of gastric cells [8–10].

Nitric oxide (NO) produced in the stomach is strongly involved in inflammatory and vascular processes, and may exert both protective and deleterious effects during gastric ulceration [11]. Endothelial nitric oxide synthase (eNOS)-produced NO exerts protective actions by increasing vasodilatation and blood flow, and also reduces endothelial leukocyte interactions in the microcirculation [12]. Furthermore, expression and activation of inducible nitric oxide synthase (iNOS) by constitutive and recruited cells during gastric ulceration leads to increased NO expression, which enhances tissue injury by evoking inflammatory cell infiltration and edema formation. Thus, the balance between iNOS/eNOS expression and activity in gastric tissue is important for adequate production of NO, which contributes to the maintenance of the structure of gastric tissue in response to aggressive agents [13,14].

The main currently available gastric ulcer treatment involves oral administration of histamine receptor antagonists (H2-Ras) and/or proton pump inhibitors (PIPs), which act by inhibiting gastric secretion. As gastric ulcers are caused by a complex mechanism, the search for new therapeutic pathways has been the target of recent investigations.

Peroxisome proliferator-activated receptor (PPAR) is a transcription factor of the nuclease hormone receptor superfamily. Three isoforms have been identified, i.e. PPARα, PPARβ/δ and PPARγ; they are broadly distributed in the organism and are responsible for regulating important physiological process. PPAR isoforms play key roles in the regulation of adipogenesis, insulin sensitivity and energy homeostasis [15,16]. Evidence has shown that PPAR regulates several actions of immune cells, exerting a marked effect on the control of inflammation. The mechanisms of action are complex and not yet completely understood, as post-transcriptional mechanisms have been proposed for the α and δ isoforms [17,18], and PPARγ activation can induce transactivation or transrepression of target genes [19–22]. PPAR pan-agonists, which activate all three PPAR isoforms, have been suggested as a potential tool as they amplify the therapeutic action and reduce the adverse effects [23,24].

Recent evidence has demonstrated that simultaneous activation of PPAR isoforms and inhibition of cyclooxygenase-2 (COX-2) may be a good approach to treat inflammatory diseases and cancer [25,26]. Despite the use of PPAR agonists in a diversity of inflammatory disorders, only little evidence has associated PPAR activation by thiazolidine molecules, such as pioglitazone and rosiglitazone, with the control and healing of gastric tissue damage. Lesions caused by ischemia/reperfusion or NSAID intake were reduced in rats pre-treated with a PPARγ agonist, and the beneficial effect was correlated to reduced mRNA levels and protein content of pro-inflammatory cytokines and enzymes, such as COX-2, iNOS, and oxidative enzymes, as well as overexpression of platelet-endothelial cell adhesion molecule (PECAM-1) and heat-shock protein 70 (HSP70) in injured gastric tissue [27–31]. More recently, it has been shown that rosiglitazone prevents indomethacin-induced gastric ulcers in type II diabetic rats [32].

Here, we investigated the efficacy and mechanisms of action of an indole-thiazolidine molecule designed to be a PPAR pan-agonist and COX inhibitor, named LYSO-7 [33], on Et/HCl-induced gastric lesions in mice. LYSO-7 provided cytoprotection by impairing neutrophil influx and reestablishing the vascular network. The latter effect was mediated by the in vivo balance of iNOS/eNOS protein expression. To our knowledge, the proposed mechanism of a PPAR pan-agonist molecule has not been previously demonstrated in vivo in an Et/HCl model, and points out the use of PPAR pan-agonists as a possible therapeutic approach for acute gastric lesions.

Materials and Methods

Animals

Male Swiss mice (20–30 g) were provided by the Central Animal House of the School of Pharmaceutical Science and the Chemistry Institute of the University of São Paulo. The animals were housed in standard cages, at room temperature (25±3°C), with 12 h dark/12 h light cycles, and supplemented with food and water ad libitum. They were transferred to the laboratory 12 hours prior to the experiments and were given water ad libitum. In all experiments, the animals were kept in cages with raised floors constructed from wide mesh, to prevent coprophagy.

Ethics statement

The project was approved by the Institutional Animal Care and Use Committee (IACUC) at the School of Pharmaceutical Sciences, University of São Paulo (Protocol number: 298 and 399). All procedures were performed according to the Brazilian Society of Science of Laboratory Animals guidelines for the proper care and use of experimental animals.

Drug treatments

Bezafibrate, pioglitazone (Sigma, St Louis, MO, USA) and LYSO-7 [33] were dissolved in water containing 0.5% (v/v) ethanol absolute, and then added to 2% carboxymethylcellulose (CMC) in distilled water as the vehicle. In some cases, before the treatments, the mice were additionally treated intraperitoneally with L-NG-nitroarginine methyl ester (L-NAME; Sigma, St Louis, MO, USA), anti-granulocyte antibody (eBioscience, San Diego, CA, USA) or GW9962 (Sigma, St Louis, MO, USA).

Gastric lesion protocol

The experiment was carried out according to the method of Mizui and Doteuchi [34]. After 12 h of fasting, the mice were randomly divided into six groups of five animals and treated as follows: 1) naïve (untreated animals); 2) CMC 0.2% aqueous solution (vehicle, 100 µL/10 g body weight); 3) bezafibrate (25 mg/kg) 4) bezafibrate (50 mg/kg); 5) LYSO-7 (5 mg/kg); 6) LYSO-7 (25 mg/kg); 7) LYSO-7 (50 mg/kg). One hour after oral treatment with the above solutions, all animals received ethanol 60% + HCl 0.03 M (100 µL/10g body weight), a concentration considered relevant to alcohol ingestion in man [35], by the oral route, to induce gastric ulcers. One hour later, the animals were sacrificed, and the stomachs were removed and opened along the greater curvature. The stomachs were gently rinsed with water to remove the gastric contents and blood clots, and then scanned. The images obtained were analyzed using “EARP” software to measure each lesion.

Determination of gastric secretion

Pylorus ligation is an important procedure that shows possible changes to gastric content parameters, e.g., total acidity and pH [36]. The assay employed here was based on a method described by Shay [37] with a few modifications. Briefly, the animals were divided into groups (n=5), according to the treatment used, as previously described. After 18 h of fasting, the animals were anesthetized; the abdomen was incised, and the pylorus ligated. Immediately after pylorus ligation, LYSO-7 was administered at a dose of 50 mg/kg. Omeprazole (30 mg/kg) was used as the positive control, and the vehicle was administered as the negative control. All the samples were administered intraduodenally. Four hours later, the animals were sacrificed; the abdomen was opened, and another ligature was placed at the esophageal end. The stomachs were removed, and the gastric contents were collected and centrifuged at 3,000 rpm (8,000×g, 25°C, 10 min). The amount of gastric juice acid (in milliliters) and the pH values were determined. The total acid secretion in the gastric juice was determined in the supernatant volume by titration (pH 7.0), using a 0.01 M NaOH solution and phenolphthalein as the indicator.

GW9662 pre-treatment

To evaluate PPARγ agonist activity, animals were pre-treated with GW9662, an PPARγ antagonist or PBS, 30 min before treatment with LYSO-7; after 1 hour, the Et/HCl solution was administered. One hour later, the animals were sacrificed, and the stomachs were removed and opened along the greater curvature. The stomachs were gently rinsed with water to remove the gastric contents and blood clots, and then scanned. The images obtained were analyzed using “EARP” software to measure each lesion.

Histological analysis

After macroscopic analysis, a small portion of each stomach was fixed in 4% formalin solution, dehydrated through increasing grades of alcohol and embedded in paraffin. Five-micrometer sections were made using a microtome, and stained with hematoxylin–eosin solution. Tissue preparations were observed and micro-photographed using an Axioplan 2 Zeiss light microscope. Five different fields of the tissue were evaluated to count the number of leukocytes.

Myeloperoxidase (MPO) assay

The activity of myeloperoxidase (MPO), a hemoprotein located in the azurophilic granules of neutrophils, was used as a biochemical marker for neutrophil infiltration into the studied tissues. MPO activity was measured according to the method originally described by Bradley [38] with some modifications, after heating the organ homogenates at 60°C for 2 h in order to inactivate endogenous catalase. Briefly, after homogenizing the tissue samples in the presence of hexadecyl trimethyl ammonium bromide (HTAB, Sigma, St Louis, MO, USA) in order to disrupt the granules, the tubes were centrifuged at 10,000 x g for 5 min. MPO activity was analyzed in the supernatants by its capacity to catalyze the oxidation of o-dianisidine dihydrochloride (Sigma, St Louis, MO, USA) in the presence of hydrogen peroxide. Absorbance was monitored at 460 nm (Spectramax Plus 384, Molecular Devices Inc., Sunnyvale, USA) and the obtained Vmax (maximum speed) parameter, related to enzyme activity, was determined using a molar extinction coefficient of 11,300 M cm-1.

Anti-granulocyte antibody treatment

To determine whether neutrophil depletion encompasses the entire period of neutrophil infiltration, test mice were injected with 50 µL (0.025 mg) of rat anti-mouse Ly6G (Gr-1) antibody, clone RB6-8C5 (eBioscience, San Diego, CA, USA), 48 h before the experiment. Previous findings showed that this Ly6G/Ly6C antibody specifically depletes mature granulocytes, especially neutrophils, and does not influence the total monocyte/macrophage count [39,40]. Control mice were injected with 50 µL of PBS. Neutrophil depletion was confirmed by optical microscopy.

Intravital microscopy

Animals were anesthetized with ketamine:xylazine (0.2:0.02 g/kg body weight), injected intraperitoneally, and tracheostomized to facilitate respiration. The femoral vein was cannulated to inject the fluorescent agent rhodamine. Leukocytes were labeled with 0.02% rhodamine immediately before blood vessel visualization. A portion of the stomach was surgically exteriorized to allow observation of the microcirculation. Animals were maintained on a special board thermostatically controlled at 37°C. The preparation was kept moist and warmed by irrigating the tissue with a warmed (37°C) Tyrode’s solution (in mg/mL: 8 NaCl; 0.2 KCl; 0.1 MgCl2; 0.058 NaH2PO4.H2O; 1 glucose; 1 NaHCO3) (pH 7.2–7.4). The rate of solution flow onto the exposed tissue was controlled (2 mL/min) to keep the preparation in continuous contact with solution. Images were obtained by fluorescence microscopy (Carl-Zeiss, Axioplan II) with epi-illumination, captured with a video camera and simultaneously transmitted to a computer. Assays were performed with animals submitted to the Et/HCl-induced ulcer model, pre-treated or not with L-NAME, and treated or not treated with LYSO-7. Five different fields of the microcirculation were evaluated to determine the percentage of blood vessels in stasis.

PPARγ mRNA expression

PPARγ mRNA transcripts were quantified in stomach tissue samples by real-time reverse transcription polymerase chain reaction (RT-PCR) analysis as previously reported. The samples were stored at −80°C in RNA-free Eppendorf tubes containing a lysis and nucleic acid purification solution (Lysis Solution 2X), homogenized by centrifugation and then digested with proteinase K (200 µg mL−1 in lysis solution) overnight at room temperature. Samples were centrifuged at 14,000 rpm for 5 min and the aqueous phase containing RNA was recovered. Total RNA extraction was performed with an ABI PRISM 6100 Nucleic Acid Prepstation (Applied Biosystems, USA) and its related chemistry. RNA was dried using a UNIVAPO 100H drier (UNIEQUIP). Subsequently, the RNA was dissolved in RNAse-free water (DEPC water) and quantified with a Nanodrop spectrophotometer (ND-420, Nanodrop Technology). Nucleic acid quality was assessed by measuring the A260/A280 ratio. Ten microliters of total RNA were used for the RT reaction following the manufacturer’s protocol (High Capacity cDNA Archive kit, Applied Biosystems, USA). The cDNA was then amplified by real-time PCR. The reaction mix (all reagents from Applied Biosystems) contained TaqMan DNA polymerase (TaqMan® Universal PCR Master Mix 2X) and primers. Real-time PCR was performed with an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, USA).

iNOS, eNOS and PPARγ protein expression

iNOS, eNOS and PPARγ protein expression in the stomach was quantified by Western blot. Briefly, stomach tissue proteins were extracted in Tris buffer (50 mM, pH 7.4) containing leupeptin (10 µg/mL), soybean trypsin inhibitor (10 µg/ml), aprotinin (2 µg/ml) and PMSF (1 mM). Homogenized proteins (87.5 µg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS–PAGE; 7%) and were electrophoretically transferred to a nitrocellulose membrane. After blocking non-specific sites with 1% casein, membranes were incubated overnight with primary rabbit polyclonal antibodies raised against iNOS (BD, CA, USA), eNOS (BD, CA, USA) and PPARγ (Santa Cruz Biotechnology, INC, CA, USA) (500 ng/mL). Membranes were washed with Tris-buffered saline containing 0.1% Tween-20 and incubated with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody. A chemiluminescent assay (HRP SuperSignalWestPico; Pierce, USA) was used to detect immunoreactive bands. The intensities of the bands were estimated by densitometry analysis and were compared to the intensity of β-actin expression.

Effects of LYSO-7 chronic treatment on body weight

To evaluate possible adverse effects associated with LYSO-7 administration (50 mg/kg, oral route), the animals were treated daily for 28 days by the oral route. Body weight and food consumption were assessed every two days. Animals treated with pioglitazone (40 mg/kg, oral route) were used as the control.

Statistical analysis

The means and standard error of the mean (SEM) of all data presented here were compared using Student’s t-test or ANOVA. Tukey’s multiple comparisons test and Dunnett’s test was used to determine the significance of differences between values according to the experimental conditions. The statistical software GraphPad Prism® was used for this purpose. p<0.05 was considered significant.

Results

In vivo LYSO-7 treatment protects Et/HCl-induced gastric tissue damage

Oral administration of Et/HCl solution caused lesions in the gastric tissue, which were prevented in a dose-dependent manner by LYSO-7 pre-treatment (Figure 1). It is noteworthy that tissue protection was seen with 25 mg/kg of LYSO-7 and with 50 mg/kg of bezafibrate, a PPAR pan-agonist (Figure 1).

thumbnail
Download:
Figure 1. Effect of LYSO-7 on Et/HCl-induced gastric tissue damage.

Male Swiss mice were treated with CMC (vehicle), LYSO-7 or bezafibrate, p.o., 1 hour before oral administration of Et/HCl solution. Gastric tissue was collected 1 hour after Et/HCl administration. (A) shows the percentage of the lesioned area and (B) shows representative images of the gastric tissue. Results are expressed as mean±SEM of 5 animals in each group. Statistical analysis was performed using ANOVA followed by Dunnett’s test. *P<0.01 vs. vehicle.

https://doi.org/10.1371/journal.pone.0076894.g001

In vivo LYSO-7 treatment enhances PPARγ gene and protein expression in the gastric tissue

Tissue PPAR expression has been highlighted as a mechanism of action of PPAR agonists. Here, we show that this is a mechanism of action of LYSO-7, as levels of PPAR mRNA and protein in the gastric tissue were markedly enhanced after in vivo LYSO-7 treatment (Figure 2). In addition, we show that the effect of LYSO-7 in Et/HCl-induced gastric lesions is dependent on its PPARγ agonist activity, as the protective effect of LYSO-7 in gastric tissue was reversed in mice pre-treated with GW9962, a recognized antagonist of PPARγ (Figure 3A and B).

thumbnail
Download:
Figure 2. Effects of LYSO-7 treatment on PPARγ gene and protein expression in Et/HCl-damaged gastric tissue.

Male Swiss mice were treated with CMC (vehicle) or LYSO-7, p.o., 1 hour before oral administration of Et/HCl solution, and gastric tissue was collected 1 hour later. (A) PPARγ gene expression and (B and C) PPARγ protein expression. Results are expressed as mean±SEM of 4 animals in each group. Statistical analysis was performed using ANOVA followed by Tukey’s test. *P<0.05 vs. vehicle.

https://doi.org/10.1371/journal.pone.0076894.g002

thumbnail
Download:
Figure 3. Role of PPARγ receptor in the protective effect of LYSO-7 on Et/HCl-induced gastric tissue damage.

Male Swiss mice were pretreated with GW9962 or PBS (i.p.) and treated with CMC (vehicle) or LYSO-7 20 min later. Et/HCl solution was administered 1 hour after the treatments. Gastric tissue was collected 1 hour later. (A) shows the percentage of the lesioned area; (B) shows representative images of the gastric tissue. Results are expressed as mean±SEM of 5 animals in each group. Statistical analysis was performed using ANOVA followed by Dunnett’s test **P<0.01 vs. vehicle.

https://doi.org/10.1371/journal.pone.0076894.g003

LYSO-7 does not impair acid gastric secretion

Data presented in Table 1 show that the pH and H+ concentration in the stomach after pylorus ligation surgery were 3.26 and 135.0, respectively. These values were modified by omeprazole treatment, represented by increased and reduced pH and H+ concentration, respectively. On the other hand, LYSO-7 treatment did not affect gastric secretion parameters.

TreatmentDosepH[H+] mequiv./L/4h
(mg/kg)
Vehicle-3.26 ± 0.12135.0 ± 10.41
Omeprazole304.24 ± 0.19*62.5 ± 5.18*
LYSO-7503.32 ± 0.17117.5 ± 18.33

Table 1. Effects of LYSO-7 and omeprazole treatment on biochemical parameters of gastric juice obtained from mice with pylorus ligation.

Results are mean±SEM of 5 mice in each group. Statistical analysis was performed using ANOVA followed by Dunnett’s test *p<0.05 vs. vehicle
CSV
Download CSV

LYSO-7 inhibits neutrophil migration into Et/HCl-damaged gastric tissue

Although neutrophil participation in Et/HCl-induced gastric damage has been proposed, its actual role in the process has not been previously shown. Here, we show that neutrophil is a hallmark of the lesion, as administration of an anti-granulocyte monoclonal antibody into mice markedly reduced both the number of granulocytes in the blood (Figure 4A) and in the gastric lesion 48 hours later (Figure 4B and C). Moreover, histological images and enhanced MPO activity in the gastric tissue showed that neutrophils rapidly accumulated in the tissue after Et/HCl administration, which were reduced by LYSO-7 treatment (Figure 5A, B and C). LYSO-7 acts by blocking neutrophil trafficking from the bone marrow, as a reduced number of circulating neutrophils and enhanced number of mature granulocytes in the bone marrow were observed in LYSO-7 treated mice (Figure 5 D and E).

thumbnail
Download:
Figure 4. Role of neutrophils in Et/HCl-damaged gastric tissue.

Male Swiss mice were pre-treated with PBS or anti-granulocyte antibody (i.p.) and blood was collected 24 or 48 hours later; Et/HCl solution was orally administered a further 48 hours later. Gastric tissue was collected 1 hour after Et/HCl delivery. (A) number of neutrophils in the blood; (B) percentage of the gastric lesion and (C) representative images of gastric tissue. Results are expressed as mean±SEM of 5 animals in each group. Statistical analysis was performed using ANOVA followed by Tukey’s test. *P<0.05 and ***P<0.001 vs. PBS treatment.

https://doi.org/10.1371/journal.pone.0076894.g004

thumbnail
Download:
Figure 5. Effects of LYSO-7 on neutrophil influx into Et/HCl-damaged gastric tissue.

Male Swiss mice were treated with CMC (vehicle) or LYSO-7, p.o., 1 hour before oral administration of Et/HCl solution and gastric tissue, blood and bone marrow perfusate were collected 1 hour later. (A) MPO activity in the gastric tissue; (B) leukocyte numbers in the gastric tissue; (C) representative image of leukocyte infiltration in the gastric tissue; (D) numbers of granulocytes in the bone marrow; (E) number of circulating neutrophils. Results are expressed as mean±SEM of 5 animals in each group. Statistical analysis was performed using ANOVA followed by Tukey’s test. *P<0.05; **P<0.01 vs. vehicle; # P<0.05; # # P<0.01 vs. naïve.

https://doi.org/10.1371/journal.pone.0076894.g005

LYSO-7 reverses blood flow stasis in Et/HCl-damaged gastric tissue, mediated by NO

The real-time intravital microscopy on the whole stomach carried out in this study is different than methods previously reported in the literature [41], as it does not involve surgical manipulation, but only exteriorization of the tissue. The data obtained here show that the Et/HCl administration caused rapid stasis in the microcirculatory network (Figure 6 A and B), and LYSO-7 pre-treatment prohibited vessel stasis (Figure 6 A and B).

thumbnail
Download:
Figure 6. Effects of LYSO-7 on microcirculatory blood flow in Et/HCl-damaged gastric tissue.

Male Swiss mice were pre-treated with L-NAME (i.p.) or treated with CMC (vehicle) or LYSO-7, p.o., 1 hour before oral administration of Et/HCl solution. Gastric tissue was surgically exposed 1 hour later after treatments for observation by intravital microscopy. (A) percentage of vessels in stasis; (B) representative images of microcirculatory vessels in the gastric tissue; (C) percentage of lesion area; (D) representative images of gastric tissue; (E) percentage of vessels in stasis; (F) representative images of microcirculatory vessels in the gastric tissue (G) MPO activity in gastric tissue. White arrows indicate vessels in stasis. Results are expressed as mean±SEM of 5 animals in each group. Statistical analysis was performed using ANOVA followed by Tukey’s test. **P<0.01 vs. vehicle; *P<0.05 vs. vehicle + L-NAME and # # P<0.01 vs. naïve.

https://doi.org/10.1371/journal.pone.0076894.g006

NO has been proposed as protective endogenous mediator of gastric damage induced by different agents. Here, we show that pre-treatment with L-NAME, a non-specific inhibitor of NO synthesis, enhanced gastric lesions caused by Et/HCl administration and partially inhibited the protective effect of LYSO-7 (Figure 6C and D). Furthermore, L-NAME treatment blocked the action of LYSO-7 on gastric microcirculatory blood flow (Figure 6E and F), but did not alter the reduced neutrophil influx into the gastric area caused by LYSO-7 (Figure 6 G).

LYSO-7 treatment inhibits iNOS expression and enhances eNOS protein expression in Et/HCl-damaged gastric tissue

Based on the evidence supporting a role for NO in the protective effects of LYSO-7 in Et/HCl-damaged gastric tissue, and since eNOS/iNOS imbalance is involved in gastric ulcer disease, the actions of LYSO-7 on the protein expression of NOS enzymes were investigated in gastric tissue. The data presented in Figure 7 show that LYSO-7 inhibited iNOS and enhanced eNOS protein expression.

thumbnail
Download:
Figure 7. Effects of LYSO-7 on NOS expression in Et/HCl-damaged gastric tissue.

Male Swiss mice were treated with CMC (vehicle) or LYSO-7, p.o., 1 hour before oral administration of Et/HCl solution and gastric tissue was collected 1 hour later. (A) iNOS; (B) eNOS protein expression on gastric tissue (C) representative image of gel electrophoresis. Results are expressed as mean±SEM of 4 animals in each group. Statistical analysis was performed using ANOVA followed by Tukey’s test. *P<0.05 vs. vehicle and # p<0.05 vs. naïve.

https://doi.org/10.1371/journal.pone.0076894.g007

LYSO-7 treatment does not alter body weight

In order to evaluate a possible adverse effect of LYSO-7, changes in body weight were evaluated for 28 days. The data show that LYSO-7 treatment did not alter the cumulative weight change or food intake. In contrast, pioglitazone treatment evoked significant weight loss, which was not dependent on impaired feed intake (Figure 8).

thumbnail
Download:
Figure 8. Effects of chronic LYSO-7 treatment on body weight and food intake.

Male Swiss mice were treated with CMC (vehicle), pioglitazone or LYSO-7, p.o., once a daily for 28 days. (A) cumulative weight change (%); (B) food intake. Results are expressed as mean±SEM of 5 animals in each group. Statistical analysis was performed using ANOVA followed by Tukey’s test. *P<0.05 vs. vehicle.

https://doi.org/10.1371/journal.pone.0076894.g008

Discussion and Conclusions

The effectiveness of preventive and therapeutic approaches for gastric ulcers has been limited to one pathway, i.e. proton pump inhibition, and the adverse effects of drugs [42]. Using an acute experimental model of gastric lesions, we show here that a indole-thiazolidine molecule, a PPAR pan-agonist and COX inhibitor named LYSO-7, does not affect gastric secretion, but causes cytoprotection by inhibiting neutrophil influx into the injured area and by maintaining blood flow in the gastric microcirculatory network. The latter effect is mediated by NO, which seems to be produced by eNOS.

The thiazolidine-2,4-dione region of the thiazolidione molecule binds to the retinoid X receptor (RXR) coupled to PPARs to form heterodimeric complexes, which then bind to the peroxisome proliferator response element (PPRE) gene promoter, leading to the regulation of gene transcription [43,44]. Although LYSO-7 maintains the thiazolidine-2,4-dione group, it is an indole-substituted properly synthesized to also display inhibitory activity against COX [33]. In vitro studies had already shown the PPAR pan-agonist activity of LYSO-7 [33], and here we confirm that the activity is maintained in vivo, as levels of PPARγ gene and protein expression were enhanced by LYSO-7 treatment. It is noteworthy that the expression of PPAR is a known end-point of PPAR activation [16]; however, the effect of a PPAR pan-agonist on gastric tissue has been shown here for the first time. Furthermore, we have shown that the cytoprotective effect of LYSO-7 is dependent on PPARγ, as the in vivo antagonism of the receptor by GW9962 abolished the inhibitory action of LYSO-7 in Et/HCl-induced ulcers. These data corroborate the notion that the γ isoform seems to be the main class of PPAR in gastric tissue [27–31]. It is worth mentioning that GW9962 has been previously used to determine the PPAR agonistic activity of newly synthesized compounds and to clarify the mechanisms of action of PPARγ [45–49].

Neutrophil influx has been observed in several models of gastric ulcers, and they have been thought to act as an inducer of the harmful process [50,51]. The participation of neutrophils in acute Et/HCl-induced gastric lesions in mice was shown here, as they rapidly accumulated in the injured tissue and in vivo neutrophil depletion significantly reduced the injured area. Together, these data corroborate the idea that inhibition of neutrophil recruitment may be a target for anti-gastric ulcer therapy [52,53], and that this can be modulated by LYSO-7 treatment.

The role of PPAR activation on neutrophil influx has been shown in different models of inflammation, and the majority of them show an inhibitory effect on the process [19,21,54]. The mechanisms involve the direct inhibition of leukocyte-endothelial interactions and chemotaxis [55,56] or impaired chemotactic mediator secretion [57–59]. Our data show, for the first time, that a PPAR agonist affects the trafficking of neutrophils from the bone marrow, as gastric-injured mice pre-treated with LYSO-7 presented higher and lower numbers of neutrophils in the bone marrow and blood, respectively. Our previous results indicate that LYSO-7 may act directly on the locomotory functions of neutrophils. N-formyl-l-methionyl-l-leucyl-l-phenylalanine (fMLP)-induced leukocyte-endothelial interactions in the mesenteric microcirculation are impaired in LYSO-7 treated rats, depending on reduced gene and protein expression of the CD62L and CD18 adhesion molecules by neutrophils (Farsky et al., personal communication). The results obtained in the present study contribute to this evidence, as the inhibitory effect on neutrophil trafficking was not dependent on NO mediation. The reduced neutrophil influx into gastric lesion caused by LYSO-7 was not modified by in vivo L-NAME treatment.

In contrast, maintenance of the surface mucosal microcirculatory blood flow by LYSO-7 treatment occurred via NO mediation, and seemed to be dependent on reduced and increased protein expression of iNOS and eNOS, respectively. A beneficial role of NO on gastric ulcers has been shown, as the in vivo blockade of both eNOS and iNOS favors the development of gastric lesions and treatments with NO donors heal lesions [60–62]. Although it has been shown that enhanced activities of iNOS and eNOS in arthritic rats are responsible for the aggravation of cold-resistant stress-induced gastric lesions [61], most studies have demonstrated that a shift in the eNOS/iNOS balance protects gastric tissue [13,62,63]. These data are corroborated here, as LYSO-7 promoted a shift in eNOS/iNOS expressed proteins in gastric tissue. It has been shown that PPAR selective agonists favor the shift of the eNOS/iNOS balance in renal tissue after ischemia–reperfusion injury, in endothelial cells after glycation-end product activation, and during vasoconstriction in mesentery vessels [64–67]. Nevertheless, it seems that activation of the three isoforms of PPAR are involved in NO-mediated gastroprotection, as the shift in eNOS/iNOS expression and the reversion of glutathione peroxidase and reductase levels in the damaged stomach were not detected after equivalent treatment with pioglitazone, a selective PPARγ agonist (data not shown). Further assays are being carried out to confirm this hypothesis.

The development of PPAR pan-agonists has been focused on the reduction of adverse effects, as they act as partial agonists of two or more isoforms of the receptor [23,68]. Although the data are preliminary, LYSO-7 did not modify body weight, which was reduced by equivalent treatment with pioglitazone. In addition, no alterations to biochemical and hematological parameters or on the morphology of the heart, spleen, liver, lung and kidney were observed (data not shown). Considering that the therapeutic efficacy of PPAR agonists is a worrying challenge [68], additional toxicity and kinetics assays were performed to assure the efficacy of LYSO-7.

In summary, we have shown the in vivo actions of LYSO-7 on the mechanisms of gastric ulcer pathogenesis. We have also demonstrated that inhibition of neutrophil migration and a shift in the eNOS/iNOS balance completely abrogate gastric tissue lesions. Based on the mechanism elucidated here, LYSO-7 may be employed to treat neutrophil-mediated diseases and to reestablish damaged microcirculatory networks.

Author Contributions

Conceived and designed the experiments: SHPF JRS MNM. Performed the experiments: JRS IDM SFPR ST. Analyzed the data: JRS IDM SFPR ST MNM SLG IRP SHPF. Contributed reagents/materials/analysis tools: MNM SLG IRP SHPF. Wrote the manuscript: SHPF JRS.

References

  1. 1. Lemos M, Santin JR, Júnior LC, Niero R, Andrade SF (2011) Gastroprotective activity of hydroalcoholic extract obtained from the leaves of Brassica oleracea var. acephala DC in different animal models. J Ethnopharmacol 138: 503-507. doi:https://doi.org/10.1016/j.jep.2011.09.046. PubMed: 21986229.
  2. 2. Sung NY, Choi KS, Park EC, Park K, Lee SY et al. (2007) Smoking, alcohol and gastric cancer risk in Korean men: the National Health Insurance Corporation Study. Br J Cancer 97: 700-704. doi:https://doi.org/10.1038/sj.bjc.6603893. PubMed: 17637680.
  3. 3. Li CY, Xu HD, Zhao BT, Chang HI, Rhee HI (2008) Gastroprotective effect of cyaniding 3-glucoside on ethanol-induced gastric lesions in rats. Alcohol 42: 683-687. doi:https://doi.org/10.1016/j.alcohol.2008.08.009. PubMed: 19038699.
  4. 4. Alvarez-Suarez JM, Dekanski D, Ristić S, Radonjić NV, Petronijević ND et al. (2011) Strawberry polyphenols attenuate ethanol-induced gastric lesions in rats by activation of antioxidant enzymes and attenuation of MDA increase. PLOS ONE 6: e25878. doi:https://doi.org/10.1371/journal.pone.0025878. PubMed: 22016781.
  5. 5. Dembinski A, Warzecha Z, Ceranowicz P, Cieszkowski J, Sendur R et al. (2011) Involvement of Cyclooxygenase-2 Activity in Therapeutic Effect of Ghrelin in the Course of Ethanol-Induced Gastric Ulcers in Rats. Gastroenterology 140: S-315.
  6. 6. Ismail IF, Golbabapour S, Hassandarvish P, Hajrezaie M, Abdul Majid N et al. (2012) Gastroprotective Activity of Polygonum chinense Aqueous Leaf Extract on Ethanol-Induced Hemorrhagic Mucosal Lesions in Rats. Evid Based Complement Alternat Med, 2012: 2012:404012. PubMed: 23365597.
  7. 7. Ning JW, Lin GB, Ji F, Xu J, Sharify N (2012) Preventive effects of geranylgeranylacetone on rat ethanol-induced gastritis. World J Gastroenterol 18: 2262-2269. doi:https://doi.org/10.3748/wjg.v18.i18.2262. PubMed: 22611321.
  8. 8. Guslandi M (1987) Effects of ethanol on the gastric mucosa. Dig Dis 5: 21-32. doi:https://doi.org/10.1159/000171159. PubMed: 3297432.
  9. 9. Szabo S, Vattay P (1990) Experimental gastric and duodenal ulcers. Gastroenterol Clin North Am 19: 67-85. PubMed: 2184131.
  10. 10. Medeiros JV, Gadelha GG, Lima SJ, Garcia JA, Soares PM et al. (2008) Role of the NO/cGMP/K(ATP) pathway in the protective effects of sildenafil against ethanol-induced gastric damage in rats. Br J Pharmacol 153: 721-727. doi:https://doi.org/10.1038/sj.bjp.0707605. PubMed: 18071300.
  11. 11. Muscará MN, Wallace JL (1999) Nitric Oxide. V. therapeutic potential of nitric oxide donors and inhibitors. Am J Physiol 276: G1313-G1316. PubMed: 10362633.
  12. 12. Kubes P, Suzuki M, Granger DN (1991) Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 88: 4651-4655. doi:https://doi.org/10.1073/pnas.88.11.4651. PubMed: 1675786.
  13. 13. Ma L, Wallace JL (2000) Endothelial nitric oxide synthase modulates gastric ulcer healing in rats. Am J Physiol Gastrointest Liver Physiol 279: G341-G346. PubMed: 10915643.
  14. 14. Guha P, Dey A, Chatterjee A, Chattopadhyay S, Bandyopadhyay SK (2010) Pro-ulcer effects of resveratrol in mice with indomethacin-induced gastric ulcers are reversed by L-arginine. Br J Pharmacol 159: 726-734. doi:https://doi.org/10.1111/j.1476-5381.2009.00572.x. PubMed: 20067468.
  15. 15. Fajas L, Debril MB, Auwerx J (2001) PPAR gamma: an essential role in metabolic control. Nutr Metab Cardiovasc Dis 11: 64-69. PubMed: 11383325.
  16. 16. Lahiri S, Sen T, Palit G (2009) Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats. Eur J Pharmacol 609: 118-125. doi:https://doi.org/10.1016/j.ejphar.2009.03.005. PubMed: 19281808.
  17. 17. Meissner M, Hrgovic I, Doll M, Naidenow J, Reichenbach G et al. (2010) Peroxisome proliferator-activated receptor {delta} activators induce IL-8 expression in nonstimulated endothelial cells in a transcriptional and posttranscriptional manner. J Biol Chem 285: 33797-33804. doi:https://doi.org/10.1074/jbc.M110.137943. PubMed: 20592029.
  18. 18. Lee JH, Kim H, Woo JH, Joe EH, Jou I (2012): 11, 2012) 2/MCP-1 expression in IFN-γ-stimulated astrocytes by increasing MAPK phosphatase-1 mRNA stability. J Neuroinflammation 9: 10.1186/1742-2094-9-34. PubMed: 22339770.
  19. 19. Long EM, Klimowicz AC, Paula-Neto HA, Millen B, McCafferty DM et al. (2011) A subclass of acylated anti-inflammatory mediators usurp Toll-like receptor 2 to inhibit neutrophil recruitment through peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A 108: 16357-16362. doi:https://doi.org/10.1073/pnas.1100702108. PubMed: 21930915.
  20. 20. Yang X, Kume S, Tanaka Y, Isshiki K, Araki S et al. (2011) GW501516, a PPARδ agonist, ameliorates tubule interstitial inflammation in protein uric kidney disease via inhibition of TAK1-NFκB pathway in mice. PLOS ONE 6: e25271. doi:https://doi.org/10.1371/journal.pone.0025271. PubMed: 21966476.
  21. 21. Farnesi-de-Assunção TS, Alves CF, Carregaro V, de Oliveira JR, da Silva CA et al. (2012) PPAR-γ agonists, mainly 15d-PGJ(2), reduce eosinophil recruitment following allergen challenge. Cell Immunol 273: 23-29. doi:https://doi.org/10.1016/j.cellimm.2011.11.010. PubMed: 22192475.
  22. 22. Wu L, Yan C, Czader M, Foreman O, Blum JS et al. (2012) Inhibition of PPARγ in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis. Blood 119: 115-126. doi:https://doi.org/10.1182/blood-2011-06-363093. PubMed: 22053106.
  23. 23. Feldman PL, Lambert MH, Henke BR (2008) PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? Curr Top Med Chem 8: 728–749. doi:https://doi.org/10.2174/156802608784535084. PubMed: 18537685.
  24. 24. Zhang LS, Wang SQ, Xu WR, Wang RL, Wang JF (2012) Scaffold-based pan-agonist design for the PPARα, PPARβ and PPARγ receptors. PLOS ONE 7: e48453. doi:https://doi.org/10.1371/journal.pone.0048453. PubMed: 23119024.
  25. 25. Pancione M, Forte N, Sabatino L, Tomaselli E, Parente D et al. (2009) Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. Hum Pathol 40: 714-725. doi:https://doi.org/10.1016/j.humpath.2008.08.019. PubMed: 19121846.
  26. 26. Meyer S, Vogt T, Landthaler M, Berand A, Reichle A et al. (2009) Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. PPAR Res, 2009: 2009:848645. PubMed: 19639032.
  27. 27. Konturek PC, Brzozowski T, Kania J, Konturek SJ, Kwiecien S et al. (2003) Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat. Eur J Pharmacol 472: 213-220. doi:https://doi.org/10.1016/S0014-2999(03)01932-0. PubMed: 12871756.
  28. 28. Takagi T, Naito Y, Ichikawa H, Tomatsuri N, Katada K et al. (2004) A PPAR-gamma ligand, 15-deoxy-Delta12, 14-prostaglandin. J Volumes 2, inhibited gastric mucosal injury induced by ischemia-reperfusion in rats. Redox Rep 9:376-981.
  29. 29. Villegas I, Martín AR, Toma W, de la Lastra CA (2004) Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation. Eur J Pharmacol 505: 195-203. doi:https://doi.org/10.1016/j.ejphar.2004.10.020. PubMed: 15556153.
  30. 30. Brzozowski T, Konturek PC, Pajdo R, Kwiecień SN, Konturek S et al (2005) Agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma): a new compound with potent gastroprotective and ulcer healing properties. Inflammopharmacology 13: 317-330. doi:https://doi.org/10.1163/156856005774423908. PubMed: 16259750.
  31. 31. Konturek PC, Brzozowski T, Burnat G, Szlachcic A, Koziel J et al. (2010) Gastric ulcer healing and stress-lesion preventive properties of pioglitazone are attenuated in diabetic rats. J Physiol Pharmacol 61: 429-436. PubMed: 20814070.
  32. 32. Morsy MA, Ashour OM, Fouad AA, Abdel-Gaber SA (2010) Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats. Clin Exp Pharmacol Physiol 37: 173-177. doi:https://doi.org/10.1111/j.1440-1681.2009.05250.x. PubMed: 19566821.
  33. 33. Santin JR, Uchôa FD, Lima MD, Rabello MM, Machado ID et al. (2013) Chemical synthesis, docking studies and biological effects of a pan peroxisome proliferator-activated receptor agonist and cyclooxygenase inhibitor. Eur J Pharm Sci 48: 689-697. doi:https://doi.org/10.1016/j.ejps.2012.12.029. PubMed: 23305993.
  34. 34. Mizui T, Doteuchi M (1983) Effect of polyamines on acidified ethanol-induced gastric lesion in rats. Jpn J Pharmacol 33: 939–945. doi:https://doi.org/10.1254/jjp.33.939. PubMed: 6580476.
  35. 35. Goso Y, Ueno M, Hotta K, Ishihara K (2007) Protective effects of the whisky congeners on ethanol-induced gastric mucosal damage. Alcohol Clin Exp Res 31: 390-394. doi:https://doi.org/10.1111/j.1530-0277.2006.00319.x. PubMed: 17295722.
  36. 36. Lakshmi V, Singh N, Shrivastva S, Mishra SK, Dharmani P et al. (2010) Gedunin and photogedunin of Xylocarpus granatum show significant anti-secretory effects and protect the gastric mucosa of peptic ulcer in rats. Phytomedicine 17: 569–574. doi:https://doi.org/10.1016/j.phymed.2009.10.016. PubMed: 19962286.
  37. 37. Shay H, Komarov SA, Fels SS, Meranze D, Gruenstein M et al. (1945) A simple method for the uniform production of gastric ulceration in the rat. Gastroenterology 5: 43–61.
  38. 38. Bradley PP, Priebat DA, Christensen RD, Rothstein G (1982) Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78: 206-209. doi:https://doi.org/10.1111/1523-1747.ep12506462. PubMed: 6276474.
  39. 39. Conlan JW, North RJ (1994) Neutrophils are essential for early anti-Listeria defense in the liver, but not in the spleen or peritoneal cavity, as revealed by agranulocyte-depleting monoclonal antibody. J Exp Med 179: 259-268. doi:https://doi.org/10.1084/jem.179.1.259. PubMed: 8270870.
  40. 40. Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE (2008) Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol 83: 64-70. PubMed: 17884993.
  41. 41. Ohno T, Katori M, Nishiyama K, Saigenji K (1995) Direct observation of microcirculation of the basal region of rat gastric mucosa. J Gastroenterol 30: 557-564. doi:https://doi.org/10.1007/BF02367779. PubMed: 8574325.
  42. 42. Krznaric Z, Ljubas Kelecic D, Rustemovic N, Vranesic Bender D, Ostojic R et al. (2011) Pharmaceutical principles of acid inhibitors: unmet needs. Dig Dis 29: 469-475. doi:https://doi.org/10.1159/000331515. PubMed: 22095012.
  43. 43. Van Beekum O, Fleskens V, Kalkhoven E (2009) Posttranslational modifications of PPAR-gamma: fine-tuning the metabolic master regulator. Obesity 17: 213-219. doi:https://doi.org/10.1038/oby.2008.473. PubMed: 19169221.
  44. 44. Dreijerink KM, Varier RA, Van Beekum O, Jeninga EH, Höppener JW et al. (2009) The multiple endocrine neoplasia type 1(MEN1) tumor suppressor regulates peroxisome proliferator-activated receptor gamma-dependent adipocyte differentiation. Mol Cell Biol 29: 5060-5069. doi:https://doi.org/10.1128/MCB.01001-08. PubMed: 19596783.
  45. 45. Naito Y, Yoshikawa T (2010) PPARgamma as a new therapeutic target in inflammatory diseases. Nihon Rinsho 68: 341-349. PubMed: 20158107.
  46. 46. Takagi T, Naito Y, Ichikawa H, Tomatsuri N, Katada K et al. (2004) A PPAR-gamma ligand, 15-deoxy-Delta12, 14-prostaglandin. J Volumes 2, inhibited gastric mucosal injury induced by ischemia-reperfusion in rats. Redox Rep 9:376-981.
  47. 47. Reddy RC, Narala VR, Keshamouni VG, Milam JE, Newstead MW et al. (2008) Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-{gamma}. Blood 112: 4250-4258. doi:https://doi.org/10.1182/blood-2007-12-128967. PubMed: 18535203.
  48. 48. Lim HA, Lee EK, Kim JM, Park MH, Kim DH et al. (2012) PPARγ activation by baicalin suppresses NF-κB-mediated inflammation in aged rat kidney. Biogerontology 13: 133-145. doi:https://doi.org/10.1007/s10522-011-9361-4. PubMed: 22033706.
  49. 49. Martin HL, Mounsey RB, Mustafa S, Sathe K, Teismann P (2012) Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson’s disease. Exp Neurol 235: 528-538. doi:https://doi.org/10.1016/j.expneurol.2012.02.017. PubMed: 22417924.
  50. 50. Wallace JL, McKnight GW, Bell CJ (1995) Adaptation of rat gastric mucosa to aspirin requires mucosal contact. Am J Physiol 268: G134-G138. PubMed: 7840196.
  51. 51. Beserra AM, Calegari PI, Souza Mdo C, Dos Santos RA, Lima JC et al. (2011) Gastroprotective and ulcer-healing mechanisms of ellagic acid in experimental rats. J Agric Food Chem 59: 6957-6965. doi:https://doi.org/10.1021/jf2003267. PubMed: 21644797.
  52. 52. Rocha NF, Oliveira GV, Araújo FY, Rios ER, Carvalho AM et al. (2011) (-)-α-Bisabolol-induced gastroprotection is associated with reduction in lipid peroxidation, superoxide dismutase activity and neutrophil migration. Eur J Pharm Sci 44: 455-461. doi:https://doi.org/10.1016/j.ejps.2011.08.020. PubMed: 21924353.
  53. 53. Bayir Y, Odabasoglu F, Cakir A, Aslan A, Suleyman H et al. (2006) The inhibition of gastric mucosal lesion, oxidative stress and neutrophil-infiltration in rats by the lichen constituent diffractaic acid. Phytomedicine 13: 584-590. doi:https://doi.org/10.1016/j.phymed.2005.07.002. PubMed: 16920514.
  54. 54. Celinski K, Dworzanski T, Korolczuk A, Piasecki R, Slomka M et al. (2011) Effects of peroxisome proliferator-activated receptors-gamma ligands on dextran sodium sulphate-induced colitis in rats. J Physiol Pharmacol 62: 347-356. PubMed: 21893696.
  55. 55. Liang YJ, Jian JH, Liu YC, Juang SJ, Shyu KG et al. (2010) Advanced glycation end products-induced apoptosis attenuated by PPAR delta activation and epigallocatechin gallate through NF-kappaB pathway in human embryonic kidney cells and human mesangial cells. Diabetes/Metab Res Rev 26: 406-416. doi:https://doi.org/10.1002/dmrr.1100.
  56. 56. Imamoto E, Yoshida N, Uchiyama K, Kuroda M, Kokura S et al. (2004) Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells. Biofactors 20: 37-47. doi:https://doi.org/10.1002/biof.5520200104. PubMed: 15096659.
  57. 57. Reilly CM, Oates JC, Cook JA, Morrow JD, Halushka PV et al. (2000) Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. J Immunol 164: 1498-1504. PubMed: 10640767.
  58. 58. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391: 79-82. doi:https://doi.org/10.1038/34178. PubMed: 9422508.
  59. 59. Wang AC, Dai X, Luu B, Conrad DJ (2001) Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am J Respir Cell Mol Biol 24: 688-693. doi:https://doi.org/10.1165/ajrcmb.24.6.4376. PubMed: 11415933.
  60. 60. El-Demerdash E, El-Mesallamy HO, Abu-Zaid NM, Gad MZ (2010) The potential therapeutic effect of nitric oxide modulators in experimentally-induced gastric ulcers. Drugs Discov Ther 4: 276-284. PubMed: 22491210.
  61. 61. Kato S, Ohkawa F, Ito Y, Amagase K, Takeuchi K (2009) Role of endothelial nitric oxide synthase in aggravation of indomethacin-induced gastric damage in adjuvant arthritic rats. J Physiol Pharmacol 60: 147-155. PubMed: 20065509.
  62. 62. Guo JS, Cho CH, Wang JY, Koo MW (2006) Differential effects of selective and non-selective inhibition of nitric oxide synthase on the expression and activity of cyclooxygenase-2 during gastric ulcer healing. Eur J Pharmacol 536: 301-308. doi:https://doi.org/10.1016/j.ejphar.2005.12.088. PubMed: 16600210.
  63. 63. Guha P, Dey A, Sarkar B, Dhyani MV, Chattopadhyay S et al. (2009) Improved antiulcer and anticancer properties of a trans-resveratrol analog in mice. J Pharmacol Exp Ther 328: 829-838. doi:https://doi.org/10.1124/jpet.108.145334. PubMed: 19066340.
  64. 64. Liang C, Ren Y, Tan H, He Z, Jiang Q et al. (2009) Rosiglitazone via up regulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products. Br J Pharmacol 158: 1865-1873. doi:https://doi.org/10.1111/j.1476-5381.2009.00450.x. PubMed: 19917066.
  65. 65. Yuen CY, Wong WT, Tian XY, Wong SL, Lau CW et al. (2011) Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase. Cardiovasc Res 90: 122-129. doi:https://doi.org/10.1093/cvr/cvq392. PubMed: 21156825.
  66. 66. Sadaghiani MS, Javadi-Paydar M, Gharedaghi MH, Fard YY, Dehpour AR (2011) Antidepressant-like effect of pioglitazone in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway. Behav Brain Res 224: 336-343. doi:https://doi.org/10.1016/j.bbr.2011.06.011. PubMed: 21704657.
  67. 67. Betz B, Schneider R, Kress T, Schick MA, Wanner C et al. (2012) Rosiglitazone affects nitric oxide synthases and improves renal outcome in a rat model of severe ischemia/reperfusion injury. PPAR Res: 2012:219319.
  68. 68. Friedland SN, Leong A, Filion KB, Genest J, Lega IC et al. (2012) The cardiovascular effects of peroxisome proliferator-activated receptor agonists. Am J Med 125: 126-133. doi:https://doi.org/10.1016/j.amjmed.2011.08.025. PubMed: 22269613.